Company news

Pulmatrix, Inc. news in 2024

Pulmatrix, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Pulmatrix and Cullgen Announce Proposed Merger

November 12, 2024

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

November 7, 2024

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

August 12, 2024

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

May 28, 2024

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine

May 16, 2024

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 14, 2024

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

March 27, 2024

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

January 7, 2024

Decks in 2024